2024-11-04 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Analysis Report

**Company Overview:** Intuitive Surgical Inc. is a leading provider of robotic-assisted minimally invasive surgery systems. 

**1. Performance Comparison:**

* **Cumulative Return:** ISRG has generated a cumulative return of 364.21%, significantly outperforming the S&P 500 (VOO) which has returned 131.78%. 
* **Outperformance:** The current outperformance of ISRG against VOO stands at 232.43, indicating a strong relative performance. This places ISRG within the top 80% of its historical outperformance range. 
* **Alpha & Beta Analysis:** ISRG exhibits a strong alpha, especially in recent years, indicating a consistent ability to outperform the market. The beta consistently fluctuates, suggesting a higher volatility compared to the market. 

**2. Recent Price Movement:**

* **Closing Price:** $506.34
* **5-Day Moving Average:** $510.23
* **20-Day Moving Average:** $498.58
* **60-Day Moving Average:** $488.1
* **Current Trend:** The stock price is currently trading above its 5-day, 20-day, and 60-day moving averages, indicating a potential upward trend.

**3. Technical Indicators:**

* **RSI:** 60.18 - Suggests the stock is currently in the overbought territory, indicating a potential for a short-term correction. 
* **PPO:** 0.01 - A positive PPO value indicates a potential for a short-term bullish trend.
* **Delta_Previous_Relative_Divergence:** 6.22 (+) - Positive divergence over the last 20 days suggests strong upward momentum.
* **Expected Return:** 12.54% - ISRG is projected to generate a higher return than the S&P 500 over the next 2 years. 

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-18 | 1.59 | $2.04B |
| 2024-07-19 | 1.48 | $2.01B |
| 2024-04-19 | 1.54 | $1.89B |
| 2023-10-20 | 1.18 | $1.74B |
| 2024-10-18 | 1.18 | $1.74B |

* **Recent Earnings:** ISRG beat analysts' earnings expectations for the latest quarter, with EPS of $1.59, exceeding the estimated $1.45. This demonstrates the company's continued strength and growth potential. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $2.04B | 67.41% |
| 2024-06-30 | $2.01B | 68.30% |
| 2024-03-31 | $1.89B | 65.87% |
| 2023-12-31 | $1.93B | 66.24% |
| 2023-09-30 | $1.74B | 66.94% |

* **Revenue Growth:** ISRG has consistently demonstrated revenue growth across the recent quarters. This indicates the company's strong market share and ability to generate consistent sales. 
* **Profitability:** ISRG exhibits a consistently high profit margin, demonstrating its efficient operations and strong pricing power. 

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $15.58B | 3.63% |
| 2024-06-30 | $14.71B | 3.58% |
| 2024-03-31 | $13.96B | 3.90% |
| 2023-12-31 | $13.31B | 4.56% |
| 2023-09-30 | $12.54B | 3.32% |

* **Strong Capital Position:** ISRG demonstrates a strong financial position with a robust equity base.
* **ROE:** The company has a healthy Return on Equity (ROE), reflecting its efficiency in generating profits from its invested capital.

**6. News & Recent Issues:**

* **Recent Earnings Release:** ISRG announced its Q3 2024 earnings on October 18th, surpassing analyst expectations. The company reported strong revenue growth and continued profitability. 
* **Market Outlook:** Analyst opinions on ISRG remain positive, citing the company's strong market position and potential for continued growth in the robotic surgery market. FINBOLD indicates a strong consensus among analysts who recommend holding or buying the stock.
* **Performance Highlights:** ISRG continues to outperform the market, with its stock price rising significantly in recent months.  The company's focus on innovation and expansion into new markets is driving its strong performance. 

**7. Overall Analysis:**

ISRG presents a compelling investment opportunity based on its strong performance, robust financial position, and favorable market outlook. The company's consistent outperformance, strong earnings growth, and commitment to innovation position it well for continued success. Although current technical indicators suggest a potential short-term correction, the long-term outlook for ISRG remains positive. Investors seeking exposure to the robotic surgery market should consider ISRG as a potential addition to their portfolio. 
